Alzheimer’s drug development now targets tau, neuroinflammation, metabolism, and synaptic dysfunction — expanding beyond amyloid toward precision medicine and combination therapy.
Multiple frontal release signs among cognitively normal older adults are associated with a higher risk for dementia and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results